|Source||Humanized (from mouse)|
|(what is this?)|
Labetuzumab (marketed under the trade name CEA-CIDE) is a humanized IgG1 monoclonal antibody for the treatment of colorectal cancer. It selectively binds to carcinoembryonic cell adhesion molecule 5. 
Also tried in patients with MTC (medullary thyroid carcinoma)
This drug was developed by Immunomedics, Inc.
- Statement On A Nonproprietary Name Adopted By The Usan Council - Labetuzumab, American Medical Association.
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|